M Fischer1, C Pöttgen, S Wechsler, M Stuschke, K Jahnke. 1. Universitäts-Hals-Nasen-Ohren-Klinik, Universität Duisburg-Essen, Hufelandstrasse 55, 45122 Essen. markus.fischer@uni-duisburg-essen.de
Abstract
BACKGROUND: The excellent results yielded by hyperfractionated and accelerated radiotherapy associated with concurrent chemotherapy in locally advanced oropharyngeal and hypopharyngeal carcinomas led to investigation of this therapeutic regimen in nasopharyngeal carcinomas also. METHODS: Thirty-five patients with stage III and IV nasopharyngeal carcinomas received accelerated hyperfractionated radiotherapy with concurrent chemotherapy (5-FU, mitomycin C + leucovorin). In the first 3 weeks of treatment five 2-Gy doses per week were delivered to the primary tumour and regional lymph nodes. The fractionation was then accelerated, with 1.4 Gy given twice daily until a total dose of 72 Gy had been administered. RESULTS: The overall objective response rate was 100%. The median follow-up period was 71 months. Salvage surgery of the lymph nodes was performed in 10 patients, revealing vital tumour tissue in 6 of these. The actuarial 5-year local control rate was 64% (95%CI: 47-81%), while overall actuarial survival at 5 years was 70% (95%CI: 53-86%). CONCLUSION: Hyperfractionated accelerated radiotherapy with concurrent chemotherapy is effective and feasible in locally advanced nasopharyngeal carcinoma.
BACKGROUND: The excellent results yielded by hyperfractionated and accelerated radiotherapy associated with concurrent chemotherapy in locally advanced oropharyngeal and hypopharyngeal carcinomas led to investigation of this therapeutic regimen in nasopharyngeal carcinomas also. METHODS: Thirty-five patients with stage III and IV nasopharyngeal carcinomas received accelerated hyperfractionated radiotherapy with concurrent chemotherapy (5-FU, mitomycin C + leucovorin). In the first 3 weeks of treatment five 2-Gy doses per week were delivered to the primary tumour and regional lymph nodes. The fractionation was then accelerated, with 1.4 Gy given twice daily until a total dose of 72 Gy had been administered. RESULTS: The overall objective response rate was 100%. The median follow-up period was 71 months. Salvage surgery of the lymph nodes was performed in 10 patients, revealing vital tumour tissue in 6 of these. The actuarial 5-year local control rate was 64% (95%CI: 47-81%), while overall actuarial survival at 5 years was 70% (95%CI: 53-86%). CONCLUSION: Hyperfractionated accelerated radiotherapy with concurrent chemotherapy is effective and feasible in locally advanced nasopharyngeal carcinoma.
Authors: D T Chua; J S Sham; D Choy; V Lorvidhaya; Y Sumitsawan; S Thongprasert; V Vootiprux; A Cheirsilpa; T Azhar; A H Reksodiputro Journal: Cancer Date: 1998-12-01 Impact factor: 6.860
Authors: Anne W M Lee; W H Lau; Stewart Y Tung; Daniel T T Chua; Rick Chappell; L Xu; Lillian Siu; W M Sze; T W Leung; Jonathan S T Sham; Roger K C Ngan; Stephen C K Law; T K Yau; Joseph S K Au; Brian O'Sullivan; Ellie S Y Pang; S K O; Gordon K H Au; Joseph T Lau Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Anne W M Lee; T K Yau; Dominique H M Wong; Elian W K Chan; Rebecca M W Yeung; W T Ng; Macy Tong; Inda S Soong; W M Sze Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-19 Impact factor: 7.038
Authors: Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: I W Dimery; L J Peters; H Goepfert; W H Morrison; R M Byers; C Guillory; K McCarthy; R S Weber; W K Hong Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544